Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable

Termination of Common Stock Purchase Agreement

On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") terminated the Common Stock Purchase Agreement, dated January 28, 2026 (the "Purchase Agreement"), by and between the Company and Tumim Stone Capital LLC ("Tumim"), effective as of such date.

As previously disclosed, the Purchase Agreement provided the Company with the right, but not the obligation, to sell to Tumim, from time to time at the Company’s sole discretion, up to $6.0 million of newly issued shares of the Company’s common stock, par value $0.0001 per share (the "Common Stock"), subject to the terms, conditions and limitations of the Purchase Agreement. The purchase price for each sale was determined under a formula based on the volume-weighted average price of the Common Stock during the applicable pricing period. The offer and sale of the shares were registered under the Company’s registration statement on Form S-3 (File No. 333-291906) pursuant to a prospectus supplement dated January 28, 2026.